Heterocyclic Arylidene Chemical Compounds vs. Glioblastoma
Overview
Glioblastoma multiforme (GBM) is a very deadly form of brain cancer. The effects of hybrid compounds of heterocyclic rhodanine and arylidene (boronic acid) were tested on GBM cancer cells. The cells were grown in 96 well culture plates and treated with four different concentrations. Since both drugs had anti-cancer properties, the hybrid had a high probability of killing a large amount of cells. The goal was to kill as many cells as possible with the lowest concentration possible. The compound of rhodanine-4-formyl-phenyl boronic acid (J MCL 1) showed a large decrease in cell count, while rhodanine-paraformaldehyde (J MCL 4) showed significant decrease with the 2.0 mg/mL concentration. The results proved that the highest concentration was most effective. It was concluded that bonds in para-position on the benzene ring cause a significant effect on cell count.
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2026
Development of Peptide-Drug Conjugates Targeting Glioblastoma Cells
ISEF · 2023
Sulforaphane and Panobinostat: A Novel Therapy for Glioblastoma Multiforme
ISEF · 2017
Inhibiting the Proliferation of Patient-Derived Glioblastoma Multiforme (GBM) Cells and U-87 MG Cell Line Using Leaf Extract of Bacopa monnieri
ISEF · 2014
Interfering with Glioblastoma Multiforme (GBM) Metabolism to Complement the Therapeutic Effects of Temozolomide
ISEF · 2020
Analyzing the Effect of Neuropilin 1 Knockdown on Conventional Chemotherapy in GBM
ISEF · 2026
Investigating the Apoptotic Mechanisms Activated in Glioblastoma Cells by Pre-Screened Cytotoxic Plants: Innovations for Novel Drug Discovery
ISEF · 2024
Design, Synthesis and Biological Evaluation of a Hybrid Boronic Acid-Quinolinone Derivative as a Novel Acid Ceramidase Inhibitor To Target Breast Cancer
CWSF · 2026
Brain-Penetrating Bioconjugate M13-CTX-PEP-1 for Targeted Glioblastoma Therapy In Silico
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair